Navigation Links
Light Sciences Oncology Elects Akbar Seddigh, Chairman of Elekta AB to Its Board of Directors
Date:11/23/2009

BELLEVUE, Wash., Nov. 23 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced the election of Akbar Seddigh, Chairman of the Board, Elekta, to a newly created seat on its board of directors. Mr. Seddigh is widely known for guiding numerous medical-product companies, including Elekta, to market leadership.

"The appointment of Akbar Seddigh brings additional strength in business development to the board," said LSO's Chairman of the Board Jeff Himawan. "Mr. Seddigh is a world leader in cancer-therapy business development. He has overseen the emergence of Elekta as the market leader in radiation treatment in oncology -- a much larger market than drug treatment in oncology."

"Akbar Seddigh has been personally instrumental in converting Elekta from a machine vendor to a true cancer-care company," added Llew Keltner, M.D., Ph.D., LSO's President and CEO.

Mr. Seddigh has held managerial positions within Volvo, AB Atomenergi, and the Geological Survey of Sweden. In 1984, he founded the medical-technology company Ortivus, where he was President until the end of the 1990s. He was recruited to Elekta's Board in 1998 and became Chairman in 1999. Elekta is an international medical-technology group, providing clinical solutions, comprehensive information systems, and services for improved cancer care and management of brain disorders. Mr. Seddigh is also Chairman of Inovation Bro (government fund), Hedson Technologies (industrial), and Belekinge Institute of Technology, and Vice-Chairman of the trade group BIO Sweden. He serves on the boards of Swedish companies Formo Services (industrial), Mentice (medical simulation), Affarsstrategerna (venture capital), Biolight (biotech), and Tobii Technology (eye control system).

"Mr. Seddigh's decades of experience, achievements, and network within cancer treatment is highly relevant for making sure LSO's product Aptocine becomes a success in a market that's vastly underserved," said Martin Olin, LSO board member and long-time Seddigh associate.

"Working on the board of Light Sciences Oncology will be one of the most interesting and exciting assignments of my career," commented Mr. Seddigh. "I look forward to helping LSO and Aptocine achieve success and leadership in the cancer-treatment community."

About Light Sciences Oncology

Light Sciences Oncology (LSO) is developing Aptocine(TM) (talaporfin sodium) for the treatment of solid tumors as well as other indications such as benign prostatic hyperplasia (BPH). Aptocine is a water-soluble drug targeted by a small, single-use, disposable drug activator included with the drug. Aptocine is designed to provide tolerable, effective, and repeatable treatments for patients. LSO has completed treatment of patients in a Phase 3 trial of Aptocine in hepatocellular carcinoma (HCC) and is currently enrolling patients in a Phase 3 trial for metastatic colorectal cancer (MCRC). LSO is also conducting clinical trials in benign prostatic hyperplasia (BPH), or enlargement of the prostate, and has clinical or preclinical programs in cardiovascular, ophthalmic, and dermatologic diseases. LSO's development organization oversees engineering, clinical trials, manufacturing, and regulatory/legal affairs. The company has positioned Aptocine to benefit an increasing number of patients with a strong portfolio of intellectual property, innovative applications in development, and an exceptionally capable and efficient team.


Contacts

Robert M. Littauer
Vice President, Chief Financial Officer and Treasurer
1-425-957-8900
bobl@lsoncology.com

Llew Keltner, M.D., Ph.D.
President and CEO
1-425-957-8900
dr_llew@lsoncology.com


Website: www.lsoncology.com

Aptocine(TM) is a trademark of Light Sciences Oncology, Inc.

SOURCE Light Sciences Oncology, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests
2. OCTANes Medical Device & Investor Forum Highlights Key Trends, Investment Opportunities
3. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
4. Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting
5. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
6. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
7. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
8. Burton Medicals New Diagnostic Examination Light, the AIM LED Provides 10 Percent More Illumination and 10 Times Greater Lamp Life
9. Presentations of Cempra Pharmaceuticals CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
10. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
11. Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... -- The global  anxiety disorders and depression treatment market  is expected ... of depression worldwide is anticipated to drive the market growth in the coming ... for antidepressants in the recent years. Continue Reading ... ... ...
(Date:1/23/2017)... , Jan 23, 2017 NeuroVive Pharmaceutical ... has signed a preclinical collaboration agreement with the Children,s Hospital ... J. Falk , M.D., a US key opinion leader in ... ... will evaluate compounds from NeuroVive,s research program, NVP015, in certain ...
(Date:1/21/2017)... Research and Markets has announced the ... Type of Test (Tumor, Clinical Chemistry, Microbiology, Esoteric), By Type ... (Tuberculosis, Influenza, Cancer, HIV/AIDS etc.), Forecast to 2022" report ... ... market segments, especially clinical lab testing, which has evolved as ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... ... institution’s inaugural K-20 Education Summit to be held March 23-25, 2017 in Tampa, ... Jan. 25, 2017. , The keynote speakers include Dr. Michelle R. Weise, executive ...
(Date:1/23/2017)... ... January 23, 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate and ... the benefits of making new water infrastructure a number one priority. “As we usher ... expect water infrastructure to become a top priority of our new political change agents.” ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... has earned organic certification under the USDA National Organic Program (NOP) for its ... process, we have established organic production and handling systems to complement our current ...
(Date:1/23/2017)... ... January 23, 2017 , ... “The Inn at the Mill”: a story of love and ... quest to become happy and content. , “The Inn at the Mill” is the ... in Germany and Vermont and is now living in Berks County on Crow Hill. ...
(Date:1/23/2017)... ... ... a time when many people celebrate romance and love by giving cards, candy, flowers or ... present, Atlanta-based Perimeter Plastic Surgery is offering a Valentine’s Day special: Spend $100 ... $50 free. , “A lot of people just buy the more predictable gift of ...
Breaking Medicine News(10 mins):